Compound ID | 1282
ETX'054
Class: Cell-wall synthesis inhibitor (PBP3 inhibitor)
| Spectrum of activity: | Gram-negative |
| Details of activity: | Efficacious In Vivo Against a P. aeruginosa Clinical Isolate |
| Institute where first reported: | Entasis Therapeutics |
| Year first mentioned: | 2019 |
| Highest developmental phase: | Preclinical |
| Development status: | Active |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.